Stock Markets May 29, 2026 08:21 AM

Tempus Gains FDA OK for Tumor-Only Use of xT CDx; Shares Tick Higher

Regulatory expansion permits tumor-only testing when matched normal samples are unavailable and may lift average selling price beginning in 2027

By Sofia Navarro TEM

Tempus AI, Inc. (NASDAQ:TEM) saw its shares rise 3.5% on Friday after receiving FDA approval to run its xT CDx next-generation sequencing platform as a tumor-only assay. The decision makes Tempus the first laboratory with FDA companion diagnostic clearances covering both tumor-only and tumor-normal comprehensive genomic profiling. The approval is expected to enable migration of the company’s DNA solid tumor portfolio to FDA-approved assays under current ADLT pricing and is projected by Tempus leadership to provide an estimated $200 average selling price benefit beginning in 2027.

Tempus Gains FDA OK for Tumor-Only Use of xT CDx; Shares Tick Higher
TEM

Key Points

  • Tempus shares rose 3.5% after FDA cleared xT CDx for tumor-only use, allowing testing without a matched normal specimen.
  • The company is now the first laboratory to hold FDA companion diagnostic approvals for both tumor-only and tumor-normal comprehensive genomic profiling.
  • Management expects an estimated $200 average selling price benefit beginning in 2027 and plans to migrate its DNA solid tumor portfolio to FDA-approved assays under current ADLT pricing.

Tempus AI, Inc. (NASDAQ:TEM) experienced a 3.5% increase in its share price on Friday following an updated FDA clearance for its xT CDx next-generation sequencing test that expands the label to include a tumor-only indication.

The expanded approval allows the company to offer the xT CDx assay when a matched normal specimen is not available, positioning Tempus as the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling.

What the approval covers

Tempus xT CDx is a tissue-based molecular profiling assay that analyzes 648 genes across all solid tumor malignancies. The test detects substitutions, insertions and deletions in those genes and reports microsatellite instability status. It uses DNA extracted from formalin-fixed, paraffin-embedded tumor tissue specimens.

As a companion diagnostic, xT CDx is used to identify colorectal cancer patients who may be candidates for targeted therapies Erbitux and Vectibix. Prior to the recent approval, the xT CDx workflow required a matched normal sample obtained from blood or saliva in order to run the assay.

Company strategy and commercial implications

Tempus said the regulatory milestone will enable the company to migrate its entire DNA solid tumor portfolio to FDA-approved assays that are priced within its current ADLT framework. Jim Rogers, Tempus' chief financial officer, characterized the approval as a milestone for both the company's regulatory and reimbursement strategy, and he noted an expectation of an estimated $200 average selling price benefit beginning in 2027 as a result of the expanded clearance.

Clinical flexibility

By permitting tumor-only testing, the expanded label gives clinicians an option when a matched normal specimen is not viable or cannot be obtained. Kate Sasser, Tempus' chief scientific officer, said the company aims to provide clinicians with advanced genomic profiling choices. She emphasized that tumor-normal matched sequencing remains an important approach, but acknowledged that matched samples are not always available and that this approval allows patients to access an FDA-cleared test even when a matched specimen cannot be provided.

Market reaction

The stock movement reflected investor response to the regulatory update. Alongside the market volatility, Tempus outlined how the clearance could shift portions of its solid tumor DNA testing business into FDA-approved price bands under existing ADLT pricing policies, with management pointing to the potential ASP uplift beginning in 2027.

Assay technical details

The xT CDx assay operates on DNA isolated from formalin-fixed, paraffin-embedded tumor tissue and is designed to identify a broad range of genetic alterations across 648 genes, including single-nucleotide substitutions and insertion-deletion events, in addition to assessing microsatellite instability.

Conclusion

The FDA's tumor-only indication for xT CDx expands testing flexibility for clinicians and may carry commercial implications for Tempus' solid tumor DNA portfolio. Management has highlighted the regulatory and reimbursement significance of the clearance and provided an estimate for future pricing benefits commencing in 2027.


Note: The article reports company statements and the FDA clearance as described by Tempus leadership; it reflects the information provided by the company regarding the approval, assay capabilities, and management expectations.

Risks

  • The projected $200 average selling price benefit is an estimate that the company expects to begin in 2027 - the realization of this benefit is uncertain.
  • Some patients still require matched normal samples for tumor-normal sequencing, and availability of such specimens can limit test use in those workflows.
  • Market reaction to regulatory news can be volatile; the reported 3.5% stock increase reflects immediate investor sentiment but does not guarantee longer-term performance.

More from Stock Markets

U.S. Officials Held Early Talks on Taking Equity Stakes in AI Firms, NOTUS Says Jun 4, 2026 Japan Sees Real Wages Climb 1.9% in April; Household Spending Drops Less Than Anticipated Jun 4, 2026 Keystone Acquisition Completes $288.22 Million IPO and Private Warrant Placement Jun 4, 2026 U.S. Futures Slip as Tech Retreats; Markets Await Jobs Report Jun 4, 2026 U.S. Officials Hold Early Talks About Acquiring Equity Stakes in AI Firms Jun 4, 2026